Corbus Pharmaceuticals is recognized as a clinical-stage precision biotechnology enterprise dedicated to developing innovative medicines for serious illnesses, with a primary emphasis on oncology and metabolic disorders. The company has gained widespread industry attention for pioneering next-generation antibody-drug conjugates (ADCs) like CRB-701 for cancer treatment and novel targeted small molecules for metabolic health and obesity management.